Krystal Biotech Stock Price, News & Analysis

Krystal Biotech, Inc. (NASDAQ: KRYS) will participate in Chardan’s 6th Annual Genetic Medicines Conference in New York on October 3-4, 2022. CEO Krish Krishnan will be featured in a fireside chat and hold investor meetings on October 4. A webcast of the presentation will be available starting at 9:00 AM ET on that date, accessible through the Company's website. Krystal Biotech is a pivotal-stage gene therapy firm focused on developing innovative treatments for serious and rare diseases.

Krystal Biotech (NASDAQ: KRYS) announced a positive opinion from the European Medicines Agency (EMA) Pediatric Committee for its Pediatric Investigation Plan (PIP) regarding B-VEC, a gene therapy for dystrophic epidermolysis bullosa (DEB). This approval allows the company to proceed with its Marketing Authorization Application (MAA) without the need for additional studies. B-VEC has orphan drug and fast track designations from the FDA. The positive opinion paves the way for enhanced market exclusivity in the EU, critical for the company's growth strategy.

Krystal Biotech, Inc. (NASDAQ: KRYS) announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference in New York from September 12-14, 2022. CEO Krish Krishnan will present and meet investors on September 13. A webcast of the presentation will be available at 2:30 PM ET on the same day and can be found on the company's website. Krystal Biotech focuses on redosable gene therapies for serious diseases, leveraging proprietary technology and in-house manufacturing capabilities.

Krystal Biotech (NASDAQ: KRYS) announced that the FDA has accepted its Biologics License Application (BLA) for B-VEC, a treatment for dystrophic epidermolysis bullosa (DEB). The application has received Priority Review status with a Prescription Drug User Fee Act (PDUFA) action date set for February 17, 2023. The FDA does not plan to hold an advisory committee meeting regarding this application. B-VEC, which has also received Fast Track and RMAT designations, aims to address the underlying causes of DEB by delivering the COL7A1 gene directly to wounds.

Krystal Biotech (NASDAQ: KRYS) announced that the FDA has accepted its Investigational New Drug (IND) application for KB407, a redosable gene therapy for cystic fibrosis (CF). Designed to treat all patients regardless of genetic mutation, KB407 aims to restore normal CFTR protein function in lung cells. The Phase 1 clinical trial will assess safety and tolerability in up to 20 adults with CF, using nebulized administration of the therapy. The trial is anticipated to commence in the second half of 2022, indicating a significant milestone for the company.

Krystal Biotech announced that the FDA has accepted its IND application for KB407, an investigational gene therapy for cystic fibrosis (CF). This therapy aims to treat all CF patients, regardless of their genetic mutation, by delivering two copies of the CFTR gene to lung cells. The Phase 1 clinical trial will assess the safety and tolerability of nebulized KB407 in up to 20 adult participants, with initiation expected in the second half of 2022. The treatment addresses a significant unmet need for roughly 10-15% of CF patients who lack effective disease-modifying options.

Krystal Biotech (NASDAQ: KRYS), a leader in redosable gene therapy, will participate in the William Blair Biotech Focus Conference 2022 on July 12-13 in New York. CEO Krish Krishnan will engage in a fireside chat and lead investor meetings on July 13. A webcast of the event will be available starting 9 AM ET on July 11. The company focuses on developing innovative therapies for serious diseases, particularly rare skin and lung conditions. For more information, visit Krystal Biotech's website.

Krystal Biotech (NASDAQ: KRYS) announced the submission of a Biologics License Application (BLA) to the FDA for B-VEC, a topical gene therapy for dystrophic epidermolysis bullosa (DEB). This therapy aims to address the COL7A1 gene deficiency, crucial for skin integrity. The BLA is supported by two clinical trials, GEM-3 and GEM-1/2, demonstrating safety and efficacy with no serious adverse events. The company plans further applications in Europe and Japan, expecting EMA submission in 2H 2022.

Krystal Biotech (NASDAQ: KRYS) announced its participation in the Goldman Sachs 43rd Annual Global Healthcare Conference scheduled for June 15, 2022. The company will be represented by Chairman and CEO Krish Krishnan in a session at 10:40 am PDT. Investors can access a live webcast of the presentation on the company’s website. Krystal Biotech is focused on developing innovative redosable gene therapies for serious conditions, particularly in skin and lung diseases.